What’s the cost of your current postoperative medication regimen?
Physician and staff time diverted to reiterating postoperative medication protocols and responding to pharmacy callbacks can add up to hours over the course of a year. Expenses can add up on the patient’s side when they fill prescriptions for multiple medications at the pharmacy.
Keeping the Pupil Open for Business
Denise Visco, MD
Pataday (olopatadine hydrochloride ophthalmic solution) 0.2% is a histamine H1 antagonist and an inhibitor of the release of histamine from the mast cells indicated for the treatment of ocular itching associated with allergic conjunctivitis.
Chondroitin sulfate/dextran/glycerol vehicle available with Cyclosporine 0.1% for all-around dry eye support
Lastacaft (alcaftadine ophthalmic solution) is a H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.
Moxeza (moxifloxacin hydrochloride ophthalmic solution) 0.5% is a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerococcus viridans*, Corynebacterium macginleyi*,...
A Cost-Benefit Analysis
Calculate the practice level impact of prescribing 503B compounded pharmacy formulations like Klarity C-Drops versus branded dry eye medications.
Vigamox (moxifloxacin HCl ophthalmic solution) 0.5% is an 8-methoxy fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus...
The MKO Melt is a nonopioid, sublingual, compounded formulation for conscious sedation during ocular and other surgical procedures.
Tobrex (tobramycin ophthalmic solution) 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative...